A5080538468- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Adenosine and Purinergic Signaling
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- RNA modifications and cancer
- Sarcoma Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Brain Metastases and Treatment
- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
Moffitt Cancer Center
2015-2024
University of South Florida
2007-2023
Sarah Cannon
2007-2018
Florida Hospital Cancer Institute
2017-2018
Tennessee Oncology
2017-2018
University Hospitals Seidman Cancer Center
2018
Memorial Sloan Kettering Cancer Center
2018
Cornell University
2018
Merck & Co., Inc., Rahway, NJ, USA (United States)
2018
Hospital Universitario Virgen Macarena
2017
Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy placebo in stage III NSCLC who did not after two or more cycles of platinum-based chemoradiotherapy.
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for second primary end point of overall survival.We randomly assigned patients, a 2:1 ratio, to receive intravenously, at dose 10 mg per kilogram body weight, or matching placebo...
Abstract Purpose: The initial goal of this study was to test the immunologic and clinical effects a new cancer vaccine consisting dendritic cells (DC) transduced with full-length wild-type p53 gene delivered via an adenoviral vector in patients extensive stage small cell lung cancer. Experimental Design: Twenty-nine were vaccinated repeatedly at 2-week intervals. Most received three immunizations. p53-specific responses evaluated, phenotype function T cells, DCs, immature myeloid analyzed...
IntroductionIn the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in primary end points progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42–65, p < 0.0001) and overall (OS) (HR 0.68, CI: 0.53–0.87, 0.00251), manageable safety no detrimental effect on patient-reported outcomes. Here, we report 3-year OS rates for all randomized...
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients Methods A total 104 patients with recurrent SCLC were randomly assigned 1:1 oral or placebo 40 mg twice daily, days 1 7, 150 200 mg/m
Purpose Alectinib has shown activity in the CNS phase I and II studies. To further evaluate this activity, we pooled efficacy safety data from two single-arm studies (NP28761 NP28673; ClinicalTrials.gov identifiers: NCT01871805 NCT01801111, respectively) patients with ALK-positive non-small-cell lung cancer (NSCLC). Patients Methods Both included NSCLC who had previously received crizotinib; all alectinib 600 mg twice per day. The primary end point both was independent review committee...
Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC).To compare ensartinib crizotinib among advanced NSCLC who had not received prior treatment ALK inhibitor.This open-label, multicenter, randomized, phase 3 trial conducted in 120 centers 21 countries enrolled 290 between July 25, 2016, November 12, 2018. Eligible were 18 years age or older advanced,...
Abstract Immune checkpoint blockade (ICB) benefits only a small subset of patients with cell lung cancer (SCLC), yet the mechanisms driving benefit are poorly understood. To identify predictors clinical to ICB, we performed immunogenomic profiling tumor samples from relapsed SCLC. Tumors who derive ICB exhibit cytotoxic T-cell infiltration, high expression antigen processing and presentation machinery (APM) genes, low neuroendocrine (NE) differentiation. However, elevated Notch signaling,...
To determine the safety, toxicity, and maximum-tolerated dose of a sequence-specific combination histone deacetylase inhibitor (HDACi), valproic acid (VPA), epirubicin in solid tumor malignancies to define clinical feasibility VPA as an HDACi.Patients were treated with increasing doses (days 1 through 3) followed by (day 3-week cycles. The study evaluated pharmacokinetic pharmacodynamic end points, toxicities, response.Forty-eight patients enrolled, 44 received at least one cycle therapy....
Purpose Src family kinase (SFK) proteins are frequently activated in cancer and can coordinate tumor cell growth, survival, invasion, angiogenesis. Given the importance of SFK signaling cancer, known cooperation between epidermal growth factor receptor (EGFR) signaling, efficacy EGFR inhibitors, we performed a phase I trial combining dasatinib, an multikinase inhibitor, with erlotinib, patients advanced non–small-cell lung cancer. Patients Methods received erlotinib for 1 week before...
Purpose The treatment of patients with advanced non–small-cell lung cancer (NSCLC) is based on clinical trials experience. Molecular characteristics that impact metabolism and efficacy chemotherapeutic agents are not used for decision making. Ribonucleotide reductase subunit 1 (RRM1) crucial nucleotide metabolism, it the dominant molecular determinant gemcitabine efficacy. Excision repair cross-complementing group gene (ERCC1), a component excision complex, important platinum-induced DNA...
Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase by increasing their access and binding DNA. This phase I trial was designed determine the toxicity profile, tolerability, recommended II dose of escalating doses HDACi vorinostat, with weekly doxorubicin. In total, 32 patients were treated; vorinostat dosed at 400, 600, 800, or 1000 mg day−1 on days 1–3, followed doxorubicin (20 m−2) day 3 for 4 weeks. Maximal tolerated determined be 800 vorinostat....
Purpose We assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival patients with advanced non–small-cell lung cancer (NSCLC). Patients Methods Eligible were randomly assigned 2:1 to the trial's experimental arm, which consisted of gemcitabine/carboplatin if low, docetaxel/carboplatin was high gemcitabine/docetaxel low high, docetaxel/vinorelbine both high. In control received gemcitabine/carboplatin. The trial powered for a 32%...
// Hatem H. Soliman 1 , Susan E. Minton Hyo Sook Han Roohi Ismail-Khan Anthony Neuger Fatema Khambati David Noyes Richard Lush Alberto A. Chiappori John D. Roberts 2 Charles Link 3 Nicholas N. Vahanian Mario Mautino Howard Streicher 4 Daniel M. Sullivan and Scott J. Antonia Lee Moffitt Cancer Center Research Institute, Tampa, Florida, USA Massey Center, Virginia Commonwealth University, Richmond, Virginia, NewLink Genetics Inc., Ames, Iowa, Therapeutics Evaluation Program, National Bethesda,...
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) second-line treatment for SCLC.In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant refractory) and brain metastases randomized 1:1 alisertib/paclitaxel placebo placebo/paclitaxel) in 28-day cycles. The primary end point was progression-free survival (PFS). Associations of c-Myc expression tumor...
Abstract Purpose: The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of in tumor microenvironment and is highly expressed non–small cell lung cancer (NSCLC). Taminadenant (PBF509/NIR178) an A2AR antagonist able to reactivate antitumor immune response. Patients Methods: In this phase I/Ib, dose-escalation/expansion study, patients with advanced/metastatic NSCLC ≥1 prior therapy received taminadenant (80–640 mg, orally, twice a day) or without spartalizumab...